glp 1 agonist liraglutide Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice GLP-1 analogs, new trend in

96% of animals (22/23) receiving autonomous delivery showed semaglutide in systemic circulation at clinically relevant levels for up to ten days following administration

It has been demonstrated to have free radical scavenging 15 , antioxidant 16, 17 , and anti-inflammatory 18, 19 effects in numerous diseases, including liver 20 and lung diseases 20, 21 , diabetes 22 , myocardial infarction 23 , and cancer 24, 25, 26

Luteolin and other flavonoids have all been explored for their potential in treating lung fibrosis, each offering unique mechanisms of action [168]

[DOI] [PubMed] [Google Scholar] 31.Moschovaki Filippidou F, et al